EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic Profiling of Primary Versus Metastatic Ewing Sarcoma for Therapeutic Target Identification

Carly Mitchell iD, Sarah Voskamp iD, Eddie Geagea iD, Deepti Anand, Jennifer Nelson iD, John Lovejoy

Life · 27.05.2026 · 16 (6) · 901

DOI: 10.3390/life16060901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 27.05.2026. Verfasst von Carly Mitchell und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Central Florida College of Medicine, Orlando, FL 32827, USA. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nemours Grants for Open Access from Library Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ewing sarcoma (ES) is a bone malignancy primarily, well known by its t(11;22)(q24;q12) chromosomal translocation. Despite high initial treatment success, ES frequently recurs, likely due to micrometastatic disease present at diagnosis but undetected during primary treatment. This study aims to characterize transcriptomic differences between primary and metastatic ES to identify genes and pathways associated with the metastatic phenotype. Using the Search Tag Analyze Resource for National Center for Biotechnology Information’s Gene Expression Omnibus, seven independent gene expression series were identified, yielding 37 metastatic and 82 primary ES tumor samples. Differentially expressed genes were defined using a significance threshold of p < 0.05 and absolute experimental log ratio > 0.1 and were analyzed using Ingenuity Pathway Analysis. This integrative transcriptomic analysis identified 753 significant molecules. Metastatic ES was characterized by upregulation of lung-associated surfactant proteins and secretoglobin family members, along with downregulation of genes involved in extracellular matrix organization. Additional genes of interest included SLC6A14, CXCL14, and TBX3, which have been implicated in tumor progression in other malignancies. These findings provide a computationally derived molecular profile associated with metastatic ES and highlight candidate genes and pathways that warrant further validation. This integrative approach offers a framework for future studies focused on understanding metastatic biology in rare pediatric cancers.

Schlagwörter

Stichwörter der Autor:innen

Ewing sarcomabiomarkersgeneticsmetastasistherapeutics

Autor:innen und Institutionen

  • University of Central Florida College of Medicine, Orlando, FL 32827, USA.
  • Department of Cardiovascular Services, Nemours Children's Health, Orlando, FL 32827, USA.
  • Department of Orthopedics, Nemours Children's Health, Orlando, FL 32827, USA.
  • Department of Research, Nemours Children's Health, Orlando, FL 32827, USA.

ORCID-Profile: Carly Mitchell, Sarah Voskamp, Eddie Geagea, Jennifer Nelson

Förderung

  • Nemours Grants for Open Access from Library Services

Zitieren

APA

Mitchell, C., Voskamp, S., Geagea, E., Anand, D., Nelson, J., & Lovejoy, J. (2026). Genetic Profiling of Primary Versus Metastatic Ewing Sarcoma for Therapeutic Target Identification. Life, 16(6), 901. https://doi.org/10.3390/life16060901

Vancouver

Mitchell C, Voskamp S, Geagea E, Anand D, Nelson J, Lovejoy J. Genetic Profiling of Primary Versus Metastatic Ewing Sarcoma for Therapeutic Target Identification. Life. 2026;16(6):901. doi:10.3390/life16060901

BibTeX
@article{Mitchell2026,
  author = {Mitchell, Carly and Voskamp, Sarah and Geagea, Eddie and Anand, Deepti and Nelson, Jennifer and Lovejoy, John},
  title = {Genetic Profiling of Primary Versus Metastatic Ewing Sarcoma for Therapeutic Target Identification},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {901},
  doi = {10.3390/life16060901}
}
Kostenlos starten →